SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.74+0.9%12:04 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bull-like who wrote (7635)5/9/1999 12:32:00 AM
From: Mkilloran  Read Replies (1) of 9523
 
Bull-like......MUSE as a niche product works and is an alternative ED product. The main market is Viagra failures,patients that cannot tolerate Viagra for adverse side effects or the fact that they use other medications like NTG.
This is only a small population of the ED patients.
Not a treat to Viagra...just an option for some ED patients.

The next product that will most likely be approved and available for ED patients is Vasomax......it's success rate is questionable and side effects like nausia and vomiting will limit it's use.

IMO it will have much less of the ED market place then what Smith Barney estimates. Time will tell.

PFE vrs Vivus as investments is not something that can be evaluated
on any even terms.

Vivus is a small bio tech that is a speculative investment at these prices and has large risk and potential large rewards on a percentage basic.

Muse and it's next generation ED product Alibra can produce a cash flow to support R&D works in progress that have more potential than the current products. For a small bio tech firm that is enough to move the stock higher.

Any comparison between PFE and VVUS is about as valid as trying to compare IBM with a small software company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News